Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration

Author(s):  Dib Jean G, Abdulmohsin Saud

Issue:  Jan/Feb 2008 - Compounding for Hospice and Cancer Patients
View All Articles in Issue

Abstract:  Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, is used in the treatment of cancer. It was the first clinically available angiogenesis inhibitor in the U.S. Recently, bevacizumab has been used by ophthalmologists in the intravitreal treatment of choroidal neovascularization in agerelated macular degeneration. Since all published trials were less than one year in duration, including follow up, no conclusion can be drawn about the long-term safety and efficacy of intravitreal bevacizumab. In open-label studies, however, intravitreal bevacizumab has yielded marked improvements in visual acuity and central retinal thickness. Compounding pharmacists who are validated in aseptic compounding can prepare intravitreal bevacizumab from the available preservative-free phosphate-buffered intravenous solution using strict aseptic technique.

Related Keywords: Jean G. Dib, BSPharm, PharmD, MS, Saud Abdulmohsin, BSPharm, MS, formulations, bevacizumab, monoclonal antibody, vascular endothelial growth factor, VEGF, intravitreal administration, vitreous, eye, ophthalmic disorders, choroidal neovascularization, aging, macular degeneration, vision loss, visual acuity, retinal thickness, aseptic compounding, sterile preparation, blood vessels, angiogenesis, antiangiogenesis, drug costs


Printer-Friendly Version

Download in electronic PDF format for $65

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Dib Jean G, Abdulmohsin Saud Jan/Feb 2008 8-14 Buy
Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J Jan/Feb 2015 70-72 Buy
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Allen Loyd V Jr Nov/Dec 2022 446-466 Buy
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H Sep/Oct 2014 418-426 Buy
Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops Sahyoun Jean-Yves, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude Jul/Aug 2022 336-341 Buy
Infliximab 1% Ophthalmic Solution Allen Loyd V Jr Jan/Feb 2017 62 Buy
Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis Mixon William, Angelle Patricea (Patsy), Chang Richard I Nov/Dec 2009 506-515 Buy
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K Jan/Feb 2013 74-85 View Sample
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP Allen Loyd V Jr May/Jun 2003 180-183 Buy
I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease McElhiney Linda F May/Jun 2012 190-195 Buy
Particle Measuring Systems - USP <797> Environmental Monitoring Solutions